New Years Rocket: NYKODE. 20% upside short-term. Nykode Therapeutics ASA, a clinical-stage biopharmaceutical company based in Oslo, Norway, specializes in developing novel immunotherapies, including vaccines for cancer and infectious diseases. Its leading product candidates are VB10.NEO, a cancer neoantigen vaccine in Phase I/IIa trials for various cancers, and VB10.16, a therapeutic vaccine in Phase II trials for HPV16-induced malignancies such as cervical cancer.
Norne Securities identified Nykode Therapeutics as a potential "New Year's rocket" for early 2025, noting that the company's market value is currently below its cash holdings. This suggests that the market may be undervaluing the company's technology and future prospects.
